{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:17:56Z","timestamp":1778800676283,"version":"3.51.4"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi231349-4\"><jats:title>Importance<\/jats:title><jats:p>Patients with breast cancer and comorbid HIV experience higher mortality than other patients with breast cancer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231349-5\"><jats:title>Objective<\/jats:title><jats:p>To compare time to cancer treatment initiation and relative dose intensity (RDI) of neoadjuvant and adjuvant chemotherapy among patients with breast cancer with vs without HIV.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231349-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A retrospective, matched cohort study enrolled women who received a diagnosis of breast cancer from January 1, 2000, through December 31, 2018. The electronic medical records of 3 urban, academic cancer centers were searched for women with confirmed HIV infection prior to or simultaneous with diagnosis of stage I to III breast cancer. Tumor registry data were used to identify 2 control patients with breast cancer without HIV for each participant with HIV, matching for study site, stage, and year of cancer diagnosis. Statistical analysis was performed from December 2022 to October 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231349-7\"><jats:title>Exposure<\/jats:title><jats:p>HIV infection detected before or within 90 days of participants\u2019 breast cancer diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231349-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was time to breast cancer treatment initiation, defined as the number of days between cancer diagnosis and first treatment. The secondary outcome was overall RDI for patients who received chemotherapy. These outcomes were compared by HIV status using Cox proportional hazards regression and linear regression modeling, respectively, adjusting for confounding demographic and clinical factors. Exploratory outcomes included instances of anemia, neutropenia, thrombocytopenia, and liver function test result abnormalities during chemotherapy, which were compared using Fisher exact tests.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231349-9\"><jats:title>Results<\/jats:title><jats:p>The study enrolled 66 women with comorbid breast cancer and HIV (median age, 51.1 years [IQR, 45.7-58.2 years]) and 132 with breast cancer alone (median age, 53.9 years [IQR, 47.0-62.5 years]). The median time to first cancer treatment was not significantly higher among patients with HIV than those without (48.5 days [IQR, 32.0-67.0 days] vs 42.5 days [IQR, 25.0-59.0 days]; adjusted hazard ratio, 0.78, 95% CI, 0.55-1.12). Among the 36 women with HIV and 62 women without HIV who received chemotherapy, the median overall RDI was lower for those with HIV vs without HIV (0.87 [IQR, 0.74-0.97] vs 0.96 [IQR, 0.88-1.00]; adjusted <jats:italic>P<\/jats:italic>\u2009=\u2009.01). Grade 3 or higher neutropenia during chemotherapy occurred among more women with HIV than those without HIV (13 of 36 [36.1%] vs 5 of 58 [8.6%]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231349-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This matched cohort study suggests that patients with breast cancer and HIV may have experienced reduced adjuvant chemotherapy RDI, reflecting greater dose reductions, delays, or discontinuation. Strategies for supporting this vulnerable population during chemotherapy treatment are necessary.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.46223","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T16:28:42Z","timestamp":1701793722000},"page":"e2346223","source":"Crossref","is-referenced-by-count":1,"title":["Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV"],"prefix":"10.1001","volume":"6","author":[{"given":"Daniel S.","family":"O\u2019Neil","sequence":"first","affiliation":[{"name":"Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehoda M.","family":"Martei","sequence":"additional","affiliation":[{"name":"Department of Medicine (Hematology-Oncology), University of Pennsylvania, Philadelphia"},{"name":"Abramson Cancer Center, Perelman School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine D.","family":"Crew","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vagelos College of Physicians and Surgeons, New York, New York"},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda S.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippos","family":"Costa","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Lim","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Michel","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vagelos College of Physicians and Surgeons, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Rubin","sequence":"additional","affiliation":[{"name":"Memorial Cancer Institute, Memorial Healthcare System, Hollywood, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Goel","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Hurley","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"},{"name":"Division of Medical Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"},{"name":"Division of Medical Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Antoni","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"},{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"issue":"1","key":"zoi231349r1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/QAI.0b013e3181b563e7","article-title":"Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.","volume":"53","author":"Harrison","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"zoi231349r2","doi-asserted-by":"publisher","year":"2016","journal-title":"J Acquir Immune Defic Syndr","DOI":"10.1097\/QAI.0000000000000960"},{"issue":"9","key":"zoi231349r4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States.","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9581","key":"zoi231349r5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"zoi231349r6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jnci\/djy010","article-title":"Risk of breast, prostate, and colorectal cancer diagnoses among HIV-infected individuals in the United States.","volume":"110","author":"Coghill","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"zoi231349r7","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States.","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi231349r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1742","article-title":"HIV infection, cancer treatment regimens, and cancer outcomes among elderly adults in the United States.","volume":"5","author":"Coghill","year":"2019","journal-title":"JAMA Oncol"},{"issue":"16","key":"zoi231349r9","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cncr.32158","article-title":"Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base.","volume":"125","author":"Coghill","year":"2019","journal-title":"Cancer"},{"issue":"20","key":"zoi231349r10","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1001\/archinte.166.20.2244","article-title":"Delays in breast cancer diagnosis and treatment by racial\/ethnic group.","volume":"166","author":"Gorin","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2","key":"zoi231349r11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2014.17322","article-title":"Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.","volume":"313","author":"Iqbal","year":"2015","journal-title":"JAMA"},{"issue":"36","key":"zoi231349r12","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.2015.63.7801","article-title":"Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the National Cancer Data Base.","volume":"33","author":"Killelea","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi231349r13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1200\/JCO.2005.04.5799","article-title":"Missed opportunities: racial disparities in adjuvant breast cancer treatment.","volume":"24","author":"Bickell","year":"2006","journal-title":"J Clin Oncol"},{"issue":"27","key":"zoi231349r14","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1200\/JCO.2005.12.633","article-title":"Racial disparities in treatment and survival among women with early-stage breast cancer.","volume":"23","author":"Hershman","year":"2005","journal-title":"J Clin Oncol"},{"key":"zoi231349r15","doi-asserted-by":"publisher","author":"Wheeler","journal-title":"J Clin Oncol","DOI":"10.1200\/JCO.2017.77.6310"},{"issue":"7","key":"zoi231349r16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1089\/apc.2013.0370","article-title":"Tolerability of chemotherapy in HIV-infected women with breast cancer: are there prognostic implications?","volume":"28","author":"Parameswaran","year":"2014","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"zoi231349r17","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.clbc.2013.11.002","article-title":"Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer.","volume":"14","author":"Singh","year":"2014","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"zoi231349r18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10549-015-3275-9","article-title":"Clinical outcomes in breast cancer patients with HIV\/AIDS: a retrospective study.","volume":"149","author":"Gomez","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"zoi231349r19","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/cid\/ciy373","article-title":"Disparities and determinants of cancer treatment in elderly Americans living with human immunodeficiency virus\/AIDS.","volume":"67","author":"Rositch","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"zoi231349r20","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00016","article-title":"Relative dose intensity and pathologic response rates in patients with breast cancer and with and without HIV who received neoadjuvant chemotherapy.","volume":"8","author":"Martei","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"zoi231349r21","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad056","article-title":"The impact of HIV infection on neoadjuvant and adjuvant chemotherapy relative dose intensity in South African breast cancer patients.","author":"O\u2019Neil","journal-title":"Oncologist"},{"issue":"9596","key":"zoi231349r22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"zoi231349r23","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"2","key":"zoi231349r24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"2","key":"zoi231349r25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaoncol.2019.4668","article-title":"Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer.","volume":"6","author":"Cespedes Feliciano","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi231349r26","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1634\/theoncologist.2013-0243","article-title":"Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research.","volume":"18","author":"Wheeler","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"zoi231349r27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes.","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi231349r28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","article-title":"Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative.","volume":"169","author":"Zhang","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"282","key":"zoi231349r30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"zoi231349r32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ijc.v151.2","article-title":"Impact of HIV infection on survival among women with stage I-III breast cancer: results from the South African Breast Cancer and HIV Outcomes study.","volume":"151","author":"Ayeni","year":"2022","journal-title":"Int J Cancer"},{"issue":"3","key":"zoi231349r33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"Time to surgery and breast cancer survival in the United States.","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi231349r34","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1245\/s10434-013-2957-y","article-title":"Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer.","volume":"20","author":"Shin","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"zoi231349r35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/jamaoncol.2015.3856","article-title":"Delayed initiation of adjuvant chemotherapy among patients with breast cancer.","volume":"2","author":"Chavez-MacGregor","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi231349r36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1245\/s10434-014-4086-7","article-title":"Wait times for breast surgical operations, 2003-2011: a report from the National Cancer Data Base.","volume":"22","author":"Liederbach","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"zoi231349r37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamasurg.2013.1680","article-title":"Delay in surgical treatment and survival after breast cancer diagnosis in young women by race\/ethnicity.","volume":"148","author":"Smith","year":"2013","journal-title":"JAMA Surg"},{"issue":"3","key":"zoi231349r38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173862","article-title":"Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: a systematic review and meta-analysis involving 186982 patients.","volume":"12","author":"He","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"zoi231349r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.5113","article-title":"Racial differences in time to breast cancer surgery and overall survival in the US military health system.","volume":"154","author":"Eaglehouse","year":"2019","journal-title":"JAMA Surg"},{"issue":"6","key":"zoi231349r40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia.","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"issue":"2","key":"zoi231349r41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2019.4648","article-title":"Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era.","volume":"6","author":"Calkins","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi231349r42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1177\/1060028019833038","article-title":"Managing pharmacotherapy in people living with HIV and concomitant malignancy.","volume":"53","author":"Olin","year":"2019","journal-title":"Ann Pharmacother"},{"key":"zoi231349r3","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance report: supplemental report: volume 24, number 1: estimated HIV incidence and prevalence in the United States, 2010-2016. February 2019. Accessed January 2, 2020. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf"},{"key":"zoi231349r29","unstructured":"U.S. Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. 2017. Accessed November 8, 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40"},{"key":"zoi231349r31","unstructured":"Sadigh? KS, Hodgeman? RM, Tapela? N, . HIV is associated with decreased breast cancer survival: a prospective cohort study. Abstract presented at: Conference on Retroviruses and Opportunistic Infections; March 4, 2019; Seattle, Washington. Accessed August 7, 2020. https:\/\/www.croiconference.org\/abstract\/hiv-associated-decreased-breast-cancer-survival-prospective-cohort-study\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2812562\/oneil_2023_oi_231349_1701192472.7332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T16:28:45Z","timestamp":1701793725000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2812562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.46223","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}